TFX vs. PODD, GMED, IART, BAX, RMD, DXCM, PEN, STVN, SWAV, and INSP
Should you be buying Teleflex stock or one of its competitors? The main competitors of Teleflex include Insulet (PODD), Globus Medical (GMED), Integra LifeSciences (IART), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Penumbra (PEN), Stevanato Group (STVN), Shockwave Medical (SWAV), and Inspire Medical Systems (INSP). These companies are all part of the "surgical & medical instruments" industry.
Teleflex vs.
Teleflex (NYSE:TFX) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
Teleflex has higher revenue and earnings than Insulet. Teleflex is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Teleflex has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
In the previous week, Teleflex had 4 more articles in the media than Insulet. MarketBeat recorded 7 mentions for Teleflex and 3 mentions for Insulet. Insulet's average media sentiment score of 1.05 beat Teleflex's score of 0.66 indicating that Insulet is being referred to more favorably in the news media.
Teleflex currently has a consensus target price of $268.92, suggesting a potential upside of 31.81%. Insulet has a consensus target price of $281.93, suggesting a potential upside of 81.07%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Teleflex.
Teleflex has a net margin of 12.71% compared to Insulet's net margin of 4.29%. Insulet's return on equity of 22.42% beat Teleflex's return on equity.
Insulet received 192 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 65.94% of users gave Insulet an outperform vote while only 59.65% of users gave Teleflex an outperform vote.
97.2% of Teleflex shares are owned by institutional investors. 1.4% of Teleflex shares are owned by company insiders. Comparatively, 0.9% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Teleflex and Insulet tied by winning 9 of the 18 factors compared between the two stocks.
Get Teleflex News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Teleflex Competitors List
Related Companies and Tools